淋巴瘤中CD-19导向的嵌合抗原受体T细胞疗法后的继发性原发性恶性肿瘤：来自意大利CART-SIE研究的报告。
Secondary primary malignancies after CD-19 directed CAR-T-cell therapy in lymphomas: A report from the Italian CART-SIE study.
作者信息
Barone Angelica, Chiappella Annalisa, Casadei Beatrice, Bramanti Stefania, Ljevar Silva, Chiusolo Patrizia, Di Rocco Alice, Tisi Maria Chiara, Barbui Anna Maria, Farina Mirko, Brunello Lucia, Di Chio Maria Chiara, Novo Mattia, Musso Maurizio, Olivieri Jacopo, Trotta Gentiana Elena, Dodero Anna, Aiello Antonella, Corradini Paolo
机构信息
Chair of Hematology, University of Milan, Milan, Italy.
Division of Hematology and Stem Cell Transplantation, Fondazione IRCCS Istituto Nazionale Dei Tumori, Milan, Italy.
出版信息
Br J Haematol. 2024 Oct;205(4):1356-1360. doi: 10.1111/bjh.19590. Epub 2024 Jun 15.
Secondary primary malignancies (SPM) have been reported after anti-BCMA or anti-CD19 chimeric antigen receptor (CAR)-T-cell therapies. While the cytotoxic effect of antecedent therapies, including chemotherapy and radiotherapy, has been well established, few data are available on risk related to CAR-T immunotherapies. The study aimed to analyse the incidence of SPM in 651 patients enrolled in the Italian prospective observational CART-SIE study. SPMs were documented in 4.3% (28/651), and the most frequent SPMs were haematological malignancies. In conclusion, the frequency of SPMs in our cohort of heavily pretreated patients receiving CAR-T was relatively low and consistent with previous studies.
在抗B细胞成熟抗原（BCMA）或抗CD19嵌合抗原受体（CAR）-T细胞治疗后，已报告出现继发性原发性恶性肿瘤（SPM）。虽然包括化疗和放疗在内的前期治疗的细胞毒性作用已得到充分证实，但关于CAR-T免疫疗法相关风险的数据却很少。该研究旨在分析参与意大利前瞻性观察性CART-SIE研究的651例患者中SPM的发生率。记录到SPM的发生率为4.3%（28/651），最常见的SPM是血液系统恶性肿瘤。总之，在我们接受CAR-T治疗的经过大量预处理的患者队列中，SPM的发生率相对较低，与先前的研究一致。
Zotero 插件